Pregnant women exposed to environmental phthalates are at an elevated risk of preterm delivery, according to a recent study in JAMA Pediatrics.
Pregnant women exposed to environmental phthalates are at an elevated risk of preterm delivery, according to a recent study in JAMA Pediatrics.
Kelly K. Ferguson, MPH, of the Department of Environmental Health Sciences, University of Michigan School of Public Health, and colleagues reviewed data from 130 women who had been pregnancy and had preterm babies from 2006-2008 and compared their exposure to phthalate metabolites with 352 randomly chosen case controls. Preterm was defined as fewer than 37 weeks of gestation.
The researchers analyzed study participants urine samples 3 times during pregnancy to determine the levels of phthalate metabolites. Phthalates are chemicals used in plastics and vinyl and are found in many consumer products, such as perfume, hair spray, soap, shampoos, nail polish, and skin moisturizers, as well as food packaging.
The phthalate metabolites “were associated with significantly increased odds of preterm birth. When spontaneous preterm births were examined alone, MEHP, mono-(2-ethyl-5-oxohexyl) phthalate, MECPP, ∑ DEHP, MBP, and mono-(3-carboxypropyl) phthalate metabolite levels were all associated with significantly elevated odds of prematurity,” the researchers wrote.
They concluded that environmental exposure to phthalates during pregnancy should be decreased to reduce the chance of preterm birth.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More